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Formation of pulmonary tertiary immune structures is a characteristic feature of advanced COPD. In the current study,
we investigated the mechanisms of tertiary lymphoid tissue (TLT) formation in the lungs of cigarette smoke-exposed
mice. We found that cigarette smoke exposure led to TLT formation that persisted following smoking cessation. TLTs
consisted predominantly of IgM positive B cells, while plasma cells in close proximity to TLTs expressed IgM, IgG, and
IgA. The presence of TLT formation was associated with anti-nuclear autoantibody (ANA) production that also persisted
following smoking cessation. ANAs were observed in the lungs, but not the circulation of cigarette smoke-exposed
mice. Similarly, we observed ANA in the sputum of COPD patients where levels correlated with disease severity and
were refractory to steroid treatment. Both ANA production and TLT formation were dependent on interleukin-1
receptor 1 (IL-1R1) expression. Contrary to TLT and ANA, lung neutrophilia resolved following smoking cessation.
These data suggest a differential regulation of innate and B cell-related immune inflammatory processes associated
with cigarette smoke exposure. Moreover, our study further emphasizes the importance of interleukin-1 (IL-1) signaling
pathways in cigarette smoke-related pulmonary pathogenesis.
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Cigarette smoking is well know for its adverse health
impacts, being a leading risk factor for most cancers, as well
as cardiovascular and respiratory diseases [1]. Currently,
emphasis has been placed on reducing smoking prevalence;
however, a greater understanding of the mechanisms of
cigarette smoke’s adverse effects on human health is equally
relevant given the addictive nature and chronic persistence
of cigarette smoking, and the burden tobacco use places
on healthcare [1].
It is widely accepted that inflammatory processes
elicited by cigarette smoke play an important role in
the pathogenesis of chronic obstructive pulmonary disease
(COPD). Over the past decades, great advances have been* Correspondence: stampfli@mcmaster.ca
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article, unless otherwise stated.made in our understanding of molecular pathways in-
volved in driving cigarette smoke-induced inflammation
[2,3]. Emphasis has been placed on innate immune cells,
including alveolar macrophages and neutrophils, for their
destructive potential as reactive oxygen species and prote-
ases released by these cells may cause tissue damage [4].
More recently, there is emerging interest in the role of the
adaptive immune system [5]. It has been postulated that
persistent inflammation associated with cigarette smoking
may promote autoimmune processes [5], as evidenced by
the occurrence of circulating autoantibodies in COPD
patients [6-8]. Mechanisms driving these autoimmune
processes remain poorly understood. Of particular interest
is the formation of pulmonary tertiary lymphoid tissues as
a potential inductive site of autoantibodies in patients with
advanced COPD.
Cytokines play a key role in orchestrating cigarette
smoke-induced inflammatory processes. To date, more
than 50 cytokines and chemokines of interest have been
reported [9]. Of particular interest is interleukin-1 (IL-1)tral Ltd. This is an Open Access article distributed under the terms of the
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Doz and colleagues demonstrated a critical role for
interleukin-1 receptor 1 (IL-1R1), the receptor for both
IL-1α and IL-1β, in cigarette smoke-induced neutrophilia
[10]. Parallel studies by Churg et al. showed that IL-1R1
KO mice were protected against cigarette smoke-induced
emphysema formation [11]. More recently, we reported
that IL-1R1 signaling pathways were required for dendritic
cell expansion and T cell activation following cigarette
smoke exposure [12]. The relative importance of IL-1R1
in tertiary lymphoid tissue (TLT) formation and autoanti-
body production is currently unknown.
The objective of this study was to investigate whether
cigarette smoke exposure leads to the formation of
pulmonary TLT and autoantibody production using a
pre-clinical model of cigarette smoke exposure, as well
as to determine the importance of IL-1R1 in these pro-
cesses. We report the formation of TLT in mice exposed to
cigarette smoke that persists following smoking cessation.
We further show the presence of broad-spectrum auto-
antibodies recognizing anti-nuclear antigens in the lungs
that persist following smoking cessation. ANA were also
observed in the sputum of COPD patients. Studies in gene
deficient mice showed that TLT and ANA formation were
IL-1R1-dependent. Our study shows that chronic cigarette
smoke exposure induces adaptive immune processes that
persist following smoking cessation. These findings fur-
ther emphasize the importance of IL-1 signaling pathways
in cigarette smoke-related pulmonary pathologies as well
as B cell and innate immune responses.
Methods
Animals
Female BALB/c mice (6-8 weeks old) were purchased
from Charles River Laboratories (Montreal, PQ, Canada).
Female, 6-8 weeks old C57BL/6 and IL-1R1-/- (C57BL/6
background) mice were purchased from The Jackson
Laboratories (Bar Harbor, ME). All mice were kept in a
12-h light-dark cycle with food and water ad libidum.
The McMaster University Animal Research Ethics Board
approved all experiments described in this study.
Cigarette smoke exposure
Mice were exposed to cigarette smoke for 4 days, 8 weeks
and 24 weeks using a whole-body exposure system (SIU48,
PROMECH LAB AB, Vintrie, Sweden) as previously
described in detail [13,14]. Briefly, mice were exposed to
the mainstream smoke of twelve 3R4F reference cigarettes
(University of Kentucky, Lexington, USA) with filters re-
moved. Mice were exposed 5 days per week, twice daily,
for 50 minutes/exposure. Total particulate matter in the
exposure chamber was measured weekly and ranged from
600 to 700 μg/L. We previously reported that cigarette
smoke exposure is well tolerated and results in cotinineand carboxyhemoglobin levels comparable to human
smokers [13]. Control animals were exposed to room
air only.
Collection of mouse specimens
Bronchoalveolar lavage (BAL), lung tissue, and blood were
collected as previously described [13,14]. Total cell counts
in the BAL were determined using a haemocytometer.
BAL cytospins were prepared for differential cell counts
and stained with Hema 3 as per the manufacturer’s in-
structions (Biochemical Sciences Inc., Swedesboro, New
Jersey, USA). At least 300 leukocytes were counted per
cytospin. BAL fluid was stored at -80°C. Blood was col-
lected by retro-orbital bleeding, serum was obtained and
stored at -80°C. For histological assessment, the left lung
was inflated with 10% neutral buffered formalin at a con-
stant pressure of 30 cm of water, and then fixed in 10%
neutral buffered formalin for 72 hours.
Sputum samples
All clinical samples were collected with patients’ informed
written consent and ethical approval from the Research
Ethic Board at McMaster University. Sputum induction
was performed as described by Pizzichini et al. [15].
Spirometry was performed according to standards of the
American Thoracic Society.
CXCL13 and anti-nuclear antibodies measurement
Bronchoalveolar lavage levels of CXCL13 were measured
by ELISA according to manufacturer’s specifications
(R&D systems, Minneapolis, MN). Anti-nuclear antibodies
were measured by ELISA. Nuclei were isolated from TC-1
cells (mouse lung epithelial cell line; grown according to
ATCC guidelines) and A549 cells (human adenocarcinoma
cell line; grown according to ATCC guidelines) according
to manufacturer’s specifications (Nuclear extraction
kit, Millipore, CA). NUNC 96-well plates (Nalge Nunc
international, NY) were dry-coated with 1 μg of nuclear
protein per well in 100 μl of water overnight at 37°C. Wells
were washed three times (0.05% TWEEN-20 in PBS) prior
to incubation with either mouse BALF (1:2 dilution), mouse
serum (1:500 dilution) or human sputum supernatant (1:10
dilution) at room temperature (RT) for two hours. Plates
were washed 3 times (0.05% TWEEN-20 in PBS) prior to
incubation with the detection antibody for 1 hour at RT.
Total mouse ANA were detected using rabbit anti-mouse
conjugated to horseradish peroxidase (HRP) (1:1000;
Invitrogen, NY). For isotype specific detection, wells
were incubated with biotinylated goat anti-mouse IgM,
IgA, or IgG (1/1000; Sigma Aldrich), washed, and
incubated with streptavidin-HRP. Total human ANA were
detected using anti-human immunoglobulin conjugated
to HRP (1:1000; Invitrogen, NY). Wells were washed
then incubated with chromogen TMB substrate (BioFX
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450 nm. The assay was validated using the serum and
BALF of the autoimmune New Zealand Black (NZB)
mouse as a positive control (Additional file 1: Figure S1).
Histological measurements
Formalin-fixed, paraffin-embedded lungs were cut into 4
μm thick cross-sections and stained with hematoxylin
and eosin. Four photos at a 16x magnification were
taken for every lung. Whole lung cross-section area
(Lungarea [pixel
2/1010]) as well as the number of bronchus-
associated TLT (TLTnumber) were determined using the
Image J Software and identified according to their distinct-
ive morphology. Data are expressed as bronchus-associated
TLTs per lung area (TLTnumber/Lungarea).
Immunohistochemical stainings
Three micrometer thick sections from formalin-fixed,
paraffin-embedded lungs were stained by immunochemis-
try for B220, CD138, IgM, IgA and IgG protein expression.
Briefly, lung sections were deparaffinized in xylene and
rehydrated in ethanol:water. Endogenous peroxidases
were blocked in 3% H2O2 in methanol. Citrate buffer
antigen retrieval was performed (45 minutes). Sections
were blocked with 1% swine serum in TBS 0.01% Tween
20. Sections were stained at 4°C overnight with either
rat anti-mouse B220 (1:50; Abcam), rabbit anti-mouse
CD138, biotinylated goat anti-mouse IgM, IgA or IgG.
Antibodies were detected with a biotinylated goat anti-
rat IgG (B220) or anti-rabbit IgG (CD138) (1:100; 1 h
RT; BioLegend) followed by streptavidin-HRP (DACO)
or directly by streptavidin-HRP (IgM, IgA, IgG). Staining
was visualized using 3-amino-9-ethylcarbazole (AEC)
substrate reagent. Sections were counterstained with
hematoxylin. Negative staining controls are presented in
Additional file 1: Figure S2.
Statistical analysis
Statistical analyses were performed using StatView Soft-
ware. Two-group comparisons were made using an un-
paired Student’s t-test with a significant threshold at 0.05.
Experimental protocols with more than two groups were
compared using a two-way ANOVA (significant threshold
at 0.05) followed, if applicable, by a Bonnferoni post-hoc
test.
Results
Chronic cigarette smoke exposure leads to persistent
tertiary lymphoid tissue formation in the lung
A characteristic histopathological feature of advanced
COPD is the emergence of pulmonary tertiary lymphoid
tissue (TLT) [16]. Using a murine model, we investigated
the time course of cigarette smoke-induced TLT formation
and whether TLTs persist following smoking cessation.BALB/c mice were exposed to cigarette smoke for 4 days,
8 weeks, and 24 weeks. Control groups were exposed to
room air only. No TLTs were observed after 4 days (data
not shown) and 8 weeks of cigarette smoke exposure
(Figure 1A). In contrast, TLTs were present in the
lungs of mice exposed to cigarette smoke for 24 weeks
(Figure 1B). No TLT formation was observed in age-
matched room air-exposed animals, providing evidence
that formation of these lymphoid structures was a conse-
quence of cigarette smoke exposure rather than aging.
Similarly, we observed TLT formation in C57BL/6 mice
following 24, but not 8, weeks of cigarette smoke exposure
(data not shown). Of note, TLT persisted in the lungs fol-
lowing smoking cessation for 60 and 120 days (Figure 1B).
Quantification of TLT provided evidence of their expansion
following smoking cessation (Figure 1C). These data dem-
onstrate that cigarette smoke exposure leads to the forma-
tion of TLTs that persist following smoking cessation.
Characterization of B cells within pulmonary tertiary
lymphoid tissue and localization of
immunoglobulin-secreting cells
Cell types found in cigarette smoke-induced pulmonary
TLTs include T cells, B cells, dendritic cells, and macro-
phages [16]. Using immunohistochemistry, we character-
ized the phenotype of B cells in TLTs of BALB/c mice
exposed to cigarette smoke for 24 weeks. Cells within
TLTs stained positive for B220, a commonly used B cell
marker (Figure 2A and 2B). The predominant isotype
expressed within TLTs was IgM (Figure 2C and 2D),
while only few IgG+ (Figure 2F) and IgA+ (Figure 2H) cells
were observed. TLT B cells displayed a distinct membrane-
staining pattern for IgM (Figure 2D) and lacked expression
of the plasma cell marker CD138+ (Figure 2J). Of note,
IgM+ (Figure 2E), IgG+ (Figure 2G), and IgA+ (Figure 2I)
cells, displaying a distinct cytoplasmic staining pattern
were observed in areas immediately adjacent to TLTs,
often nearby blood vessels. This staining pattern is indica-
tive of plasma cells, as B cell that differentiate into antibody
producing plasma cells loose surface expression of mem-
brane bound immunoglobulin while greatly expanding their
immunoglobulin synthesis machinery. This gives plasma
cells a characteristic cytoplasmic immunoglobulin-staining
pattern. This observation was supported by the presence of
cells expressing the plasma cell marker CD138+ in similar
locations (Figure 2K and 2L).
Cigarette smoke exposure elicits local but not systemic
production of anti-nuclear autoantibodies
Emerging evidence suggests that cigarette smoking elicits
autoantibody responses in susceptible individuals [6-8]. We
next investigated whether formation of TLT and accumula-
tion of plasma cells in the lungs of cigarette smoke-exposed
mice was associated with autoantibody production. We
Figure 1 Chronic cigarette smoke exposure leads to pulmonary tertiary lymphoid tissue (TLT) formation that persists following
smoking cessation. BALB/c mice were exposed to room air (open bars) or cigarette smoke (solid bars) for (A) 8 weeks ± 20 days of smoking
cessation or for (B) 24 weeks ± 60 and 120 days of smoking cessation. Lung sections were stained with hematoxylin and eosin (H&E).
(C) Pulmonary TLT were quantified using Image J software. Data represent means ± SEM; n = 5 per group. *p < 0.05.
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antibodies against nuclear antigens; a type of autoantibody
widely associated with autoimmune disorders. Anti-nuclear
antibodies (ANA) were assessed in the BALF (local) and
the serum (systemic) of cigarette smoke and room air-
exposed mice. While no increase in ANA was observed
following 4 days of cigarette smoke exposure, exposure tocigarette smoke for 8 and 24 weeks was associated
with significantly increased levels of ANA in the BALF
(Figure 3A). No increase in BALF ANA levels was ob-
served in room air-exposed mice. In mice exposed to
cigarette smoke for 8 weeks, increased ANA levels
returned to baseline following smoking cessation for
20 days. In contrast, ANA remained elevated for more
Figure 2 Plasma cells are found in close proximity with pulmonary tertiary lymphoid tissues (TLT) that mainly contain naïve B cells.
BALB/c mice were exposed to cigarette smoke for 24 weeks and lung sections were stained by immunochemistry for (A) B cells (B220), (C) IgM,
(F) IgG, (H) IgA and (J-K) plasma cells (CD138). (B) Tight clusters of B220 expressing B cells. (D) Cells expressing membrane-bound IgM within a
pulmonary TLT. (E) IgM-, (G) IgG- and (I) IgA-secreting cell (cytoplasmic staining) found adjacent to pulmonary TLTs. (J) Absence of plasma cells
inside pulmonary TLT which are generally found near pulmonary TLT or (K-L) vessels.
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smoke for 24 weeks (Figure 3A). Further analysis of BALF
ANA following 8 weeks of cigarette smoke exposure re-
vealed that the main isotypes expressed were IgG and IgA
(Figure 3B). After 24 weeks of smoke exposure, the pre-
dominant ANA isotype in the BALF was IgA (Figure 3C),
an isotype adapted for mucosal secretion. Expression of
ANA was specific to the lungs, as no increase in ANA was
observed in the serum of cigarette smoke-exposed mice
(Figure 3D). This suggests that following 8 weeks of
cigarette smoke exposure, and in the absence of TLT,
pulmonary ANA expression is transient and resolves fol-
lowing smoking cessation. In contrast, following chronic
exposure to cigarette smoke, and in the presence of TLT,
pulmonary ANA persist following smoking cessation.
ANA levels are elevated in COPD patients and are
refractory to steroid treatment
Previous clinical studies focused on serum analysis of
autoantibodies [7,17,18]. To investigate whether cigarette
smoking was associated with accumulation of autoanti-
bodies in the human lung, as observed in our animal
model (Figure 3A), ANA were assessed in the sputum
of COPD patients. ANA levels were significantly ele-
vated in the sputum of GOLD stage 2/3/4 COPD pa-
tients compared to GOLD stage 0/1 (Figure 3E) (see
Table 1 for patient descriptions). Moreover, steroid-
based therapy had no effect on sputum ANA levels
(see Table 2 for patient descriptions) (Figure 3E). To
our knowledge, this is the first study to report that
autoantibodies accumulate locally in the sputum ofCOPD patients and that they are refractory to steroid-
based therapy.
Neutrophilic inflammation Resolves following chronic
cigarette smoke exposure
In COPD patients, pulmonary inflammation may persist
following smoking cessation. We therefore investigated
whether the presence of TLT and the elevated ANA levels
were associated with persistent inflammation following
smoking cessation. BALB/c mice were exposed to cigarette
smoke for 4 days, 8 weeks, and 24 weeks, and the BAL
cellular profile was assessed 18 hours after the last smoke
exposure and following smoking cessation. We observed
significantly increased total cell numbers (TCN), mono-
nuclear cells (MNC), and neutrophils following 4 days,
8 weeks, and 24 weeks of cigarette smoke exposure
(Figure 4A-C). In mice exposed to cigarette smoke for
4 days (Figure 4A), increased numbers of total cells, MNC
and neutrophils resolved within 3 days of smoking cessa-
tion. In mice exposed for 8 weeks (Figure 4B), TCN and
MNC returned to baseline within 20 days, while the neu-
trophilia persisted. In mice exposed to cigarette smoke for
24 weeks (Figure 4C), TCN, MNC, and neutrophils de-
clined but remained significantly elevated compared to
room air controls following smoking cessation for 60 days.
Following 120 days of smoking cessation, TCN and MNC
returned to baseline levels, while neutrophilia resolved
by >95%. These findings suggest that the cellular inflam-
matory profile in the BAL resolves following smoking
cessation; although resolution of inflammation appears to
be delayed following prolonged cigarette smoke exposure.
Figure 3 Cigarette smoke exposure elicits pulmonary but not systemic anti-nuclear antibodies production. BALB/c mice were exposed to
room air (open bars) or cigarette smoke (solid bars) for 4 days, 8 weeks ± 20 days of smoking cessation or for 24 weeks ± 60 and 120 days of
smoking cessation. ANA levels were measured by ELISA in the (A) bronchoalveolar lavage fluid (BALF) and antibody isotypes dissected in mice
exposed for (B) 8 weeks and (C) 24 weeks. (D) ANA levels were also measured in the serum of mice exposed for 8 weeks ± 20 days of smoking
cessation or for 24 weeks ± 60 and 120 days of smoking cessation. (E) ANA levels were measured in the sputum of different GOLD stage subjects
(see Tables 1 and 2 for complete description) and expressed as fold increase of GOLD 0/1 subjects. (A and D) Data represent means ± SEM; n = 5-10
mice per group. *p < 0.05. (B and C) Data represent the values obtained from pooled samples from each group. Fold changes were calculated by
using the average O.D. value of the corresponding room air-exposed group as baseline expression (fold increase of 1).
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neutrophilia, elevated pulmonary anti-nuclear
antibodies and TLT formation
IL-1R1 signaling pathways play a critical role in cigarette
smoke-induced neutrophilia, dendritic cell accumulation,
and T cell activation [10,12]. We therefore investigated
the role of IL-1R1 signaling in the generation of TLT
and ANA following chronic cigarette smoke exposure.
Confirming our previous observations, no neutrophilsTable 1 Patient characteristics
Variables Gold 0/1 (n = 7) Gold 2 (n = 23) Gold 3/4 (n = 17)
Age, yr 55.7 (9.7) 62.3 (7.9) 61.0 (8.7)
Gender, F/M 3/4 11/12 8/9
FEV1, % pred. 85.4 (5.8)
* 59.2 (9.2)‡ 36.2 (8.2)#
FEV1/FVC, % 73.0 (11.3)
* 55.0 (9.9)‡ 38.3 (8.9)#
Data are expressed as mean(SD).
Values with different superscript symbols are significantly different from
each other.were found in the BAL of IL-1R1-/- mice following 24
weeks of cigarette smoke exposure (Figure 5B). Moreover,
neither TLT nor elevated ANA were observed in the
lungs of cigarette smoke-exposed IL-1R1-deficient mice
(Figure 5A,C,D). CXCL13, a B cell-attracting chemokine
that has recently been implicated in cigarette smoke-
induced TLT formation [19], was significantly increased
in cigarette smoke compared to room air-exposed wild type
mice. In contrast, levels of CXCL13 were not increased inTable 2 Patient characteristics
Variables Gold 2/3/4 no
steroid use (n = 10)
Gold 2/3/4
Steroid use (n = 19)
Age, yr 66.8 (6.5)* 59.3 (8.4)‡
Gender, F/M 4/6 10/9
FEV1, % pred. 57.0 (12.0)
* 45.4 (13.3)‡
FEV1/FVC, % 54.9 (12.8)
* 44.1 (9.1)‡
Data are expressed as mean(SD).
Values with different superscript symbols are significantly different from
each other.
Figure 4 Resolution of lung inflammation is delayed following chronic cigarette smoke exposure. BALB/c mice were exposed to room air
(open bars) or cigarette smoke (solid bars) for (A) 4 days ± 3 days of smoking cessation, (B) 8 weeks ± 20 days of smoking cessation or for (C) 24
weeks ± 60 and 120 days of smoking cessation. Data show total cell number, mononuclear cells and neutrophils in the BAL. Bars represent
means ± SEM; n = 5 per group. *p < 0.05.
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findings suggest that IL-1R1 signaling pathways play a
central role in cigarette smoke-induced innate immune
inflammatory processes as well as processes associated
with adaptive immune responses such as the formation of
tertiary lymphoid tissues and autoantibody production.
Discussion
Clinical evidence suggests that cigarette smoking leads
to TLT formation in the lung; however, the mechanisms
that lead to the formation of these tertiary lymphoid tis-
sues and their association with autoimmune processes
are at present unknown. The objective of the current
study was to investigate the mechanisms of TLT forma-
tion and autoantibody production using a mouse model
of cigarette smoke exposure.
To investigate cigarette smoke’s impact on TLT for-
mation, we utilized a well-characterized murine model
of cigarette smoke exposure [13,14,20]. We previously
reported that cigarette smoke exposure is well tolerated
and leads to cotinine and carboxyhemoglobin levels com-
parable to human smokers thus validating the experimen-
tal approach [13]. In the current study, we report that
exposure to cigarette smoke led to pulmonary TLT forma-
tion that persisted following smoking cessation. B cellswithin TLTs preferentially expressed membrane-bound
IgM, while plasma cells expressing IgM, IgG, or IgA were
located in areas adjacent to TLTs. These findings suggest
that TLTs are a site of B cell activation, leading to plasma
cell differentiation and antibody production within the
lungs.
A key observation of this study is that formation of lung
tertiary lymphoid tissues was strongly associated with
persistently increased levels of ANA following smoking
cessation. We analyzed anti-nuclear antibodies (ANA)
since they are a broad-spectrum class of autoantibodies
that are associated with a number of autoimmune disor-
ders in both humans and experimental models [21,22].
The increase in ANA levels was observed in the lungs, but
not in the circulation of cigarette smoke-exposed mice.
While we observed a transient increase in ANA IgG
following 8 weeks of cigarette smoke exposure, ANA IgA
was the predominant isotype after 24 weeks. This shift to-
wards IgA provides further evidence of local autoantibody
production, as IgA is the isotype associated with mucosal
tissues. This may signify that these autoimmune processes
are confined to the lungs and lack the systemic compo-
nent that is observed in other autoimmune diseases such
as systemic lupus erythematosus, rheumatoid arthritis, or
Sjögren’s syndrome [21,23,24].
Figure 5 Neutrophil recruitment, pulmonary tertiary lymphoid tissue development and increased ANA levels are dependent on IL-1R1
expression. C57BL/6 and IL-/R1-/- mice were exposed to room air (open bars) or cigarette smoke (solid bars) for 24 weeks. (A) Lung sections were
stained with hematoxylin and eosin (H&E). (B) Total neutrophils number was assessed in the BAL. (C) Pulmonary TLT were quantified using Image
J software. (D) Pulmonary ANA and E) CXCL13 levels were measured in the BALF by ELISA. Data represent means ± SEM; n = 5 per group.
*p < 0.05, **p < 0.01.
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COPD [16], the function of this lymphoid structures re-
main poorly understood. Studies by Bracke and colleagues
[19] suggest that TLTs do not contribute to emphysema
formation in cigarette smoke-exposed mice. While auto-
antibodies were present in cigarette smoke exposed mice
prior to TLT formation, sustained presence of ANA after
smoking cessation was only observed in the presence of
pulmonary TLTs. It is plausible that these structures might
be a site of continuous activation of B cells even following
smoking cessation and the generation of autoantibody-
producing plasma cells.
In line with our observations in cigarette smoke-exposed
mice, we show a significant increase in ANA levels in the
sputum of GOLD stage 2/3/4 COPD patients compared
to GOLD stage 0/1 subjects thus providing evidence that
sputum autoantibodies levels correlate with disease se-
verity. Of note, ANA levels in the sputum were steroid
insensitive; similar levels were observed in patients that
received steroid treatment compared to patients that
were not treated with steroids. While there is increasing
evidence that autoantibodies are detected in the circulation
of COPD patients [9-11], several reports did not confirm
these observations [19,20]. Our findings suggest that auto-
antibodies associated with COPD may be more reliablydetected in sputum and provide evidence that cigarette
smoke elicits autoimmune processes specifically within
the lungs.
Mechanistically, we demonstrated that cigarette smoke-
induced TLT formation and ANA production is IL-1R1-
dependent. These findings further highlight the importance
of IL-1R1 signaling pathways in cigarette smoke-induced
inflammation. We, and others, have previously shown that
cigarette smoke-induced neutrophilia [10,25,26] and forma-
tion of emphysematous damage is, at least in part, IL-1R1
dependent [11]. Of note, IL-1R1 signaling pathways were
required for the induction of CXCL-13, a chemokine that
plays a critical role in TLT formation following cigarette
smoke exposure [19], suggesting that the absence of TLT
in the lung of IL-1R1-/- mice may be caused by a lack
of CXCL13 upregulation. Of particular interest to our
current study is that dendritic cell expansion and T cell
activation following cigarette smoke exposure are also
IL-1R1 dependent [12]. Hence, the ability of cigarette
smoke to induce autoimmune processes may be subse-
quent to dendritic cell activation as postulated by Cosio
and colleagues [5].
To the best of our knowledge, we are the first to
document that IL-1R1 plays a critical role in cigarette
smoke-induced ANA and TLT formation. While little
Figure 6 Kinetic of the innate and adaptive responses induced
by cigarette smoke exposure and the impact of smoking
cessation. Resolution of the innate immune response (macrophages
and neutrophils) measured in the BAL is markedly delayed when
preceded by chronic exposure but can happen. Features of adaptive
immune response (pulmonary TLT formation and elevated ANA)
requires chronic exposure to be initiated but does not resolve
following cessation. Moreover, the delay in the resolution of the
innate immune response is associated with the activation of the
adaptive immune response.
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Croker et al. reported that autoimmune processes observed
in Ptp6n-/- mice (deficient in SHP1 protein) were IL-1R1
dependent [27]. Interestingly, autoimmunity in this model
was likely triggered by the host’s microflora, as germ-free
Ptp6n-/- mice did not exhibit the phenotype. While mech-
anisms leading to inflammation and autoimmunity remain
to be elucidated in the Ptp6n-/- mice, the underlying pro-
cesses are similar to the IL-1R1 dependency of cigarette
smoke-induced ANA production and BALT formation.
Contrary to the sustained production of ANA and per-
sistence of TLT, neutrophilia resolved following smoking
cessation. Of interest, the time course of resolution was
a function of the duration of cigarette smoke exposure.
Neutrophilia resolved within 3 days in an acute exposure
protocol (4 days). Following 24 weeks of cigarette smoke
exposure, inflammation resolved more slowly, as signifi-
cantly increased neutrophil numbers were observed 60
days following smoking cessation, ultimately approaching
baseline only after 120 days of cessation. This relates
to what is observed clinically where inflammation may
persist for a prolonged period following smoking ces-
sation [28,29]. It is currently not understood whether
ANA contribute to this delayed resolution. Immune
complexes are well known to propagate neutrophilic
inflammation [30] and promote neutrophil and monocyte
survival in vitro [31,32]. Alternatively, it is plausible that
ANA attenuate cigarette smoke-induced inflammatory
processes via opsonizing cellular debris and improvingtheir clearance by phagocytic cells. Moreover, whether
autoantibodies perpetuate or attenuate pathogenic mecha-
nisms may depend on antibody specificity and isotype, as
well as, the microenvironment within the target tissue.
While the consequences of elevated ANA in the lungs
of cigarette smoke-exposed mice are currently unknown,
it is of interest that adaptive immune processes such as
autoantibody production and TLT formation persisted
following smoking cessation, while innate inflammatory
processes resolved (Figure 6).
Cigarette smoke exposure is a leading risk factor for
many diseases such as cancer, cardiovascular diseases,
and COPD which reflects the complexity of its effects
on the human body. Data presented here demonstrate
that cigarette smoke induces local ANA production that
is associated with the presence of pulmonary TLTs. Our
data further highlights the importance of IL-1 signaling
pathways in innate and adaptive immune inflammatory
processes associated with COPD pathology.
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